{"url_path":"/sec/phge/8-k/2026-08-11/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-087839-index.html","accession_number":"0001213900-26-087839","cik":"0001739174","ticker":"PHGE","issuer_name":"BiomX Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1739174/0001213900-26-087839-index.html","primary_entity_key":"0001739174","primary_entity_name":"BiomX Inc."},"word_count":175,"has_tables":true,"body_markdown":"**Item 3.02 Unregistered Sales of Equity Securities.**\n\n** **\n\nThe information set forth in Item 1.01 of this Current Report\non Form 8-K is incorporated by reference into this Item 3.02. As noted above, the issuance of the Consideration Shares is\nsubject to the approval by the NYSE American of a supplemental listing application.\n\n \n\nThe shares will be issued without registration under the Securities\nAct of 1933, as amended, in reliance on Section 4(a)(2) thereof and/or Regulation S thereunder, as restricted securities.\n\n \n\n**Forward Looking Statements**\n\n \n\nThis Current Report on Form 8-K contains\nforward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding\nthe expected benefits of the transaction, the license, the Option, and the completion of the transactions described above. These statements\nare subject to risks and uncertainties, including the satisfaction of closing conditions, the results of due diligence, and the receipt\nof required approvals, including of the NYSE American, and actual results may differ materially. The Company undertakes no obligation\nto update these statements except as required by law."}